Merck Arcoxia Safety Board Allows Long-Term Trials To Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
The ongoing trials of etoricoxib are likely to continue through at least 2006. Merck is conducting the EDGE-2 and MEDAL studies to support resubmission of its NDA for the follow-on COX-2 inhibitor.
You may also be interested in...
Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
Merck’s Arcoxia “Approvable” At FDA
The agency is seeking additional safety and efficacy data for the COX-2 inhibitor, the company says. Merck is working with international regulatory agencies on labeling changes for Arcoxia to address safety issues prompted by the Vioxx withdrawal.
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal
Arcoxia's user fee date is Oct. 30, but FDA could decide to wait for 18-month cardiovascular safety data from a 20,000-patient trial comparing etoricoxib with diclofenac. Merck says it will work with regulatory authorities in 47 countries where Arcoxia is marketed to discuss potential labeling changes resulting from the Vioxx study data.